Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00838565 · ClinicalTrials.gov registry record · Phase 1
Phase I Study Of The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Intravenously Administered Doses Of PF-04236921 In Patients With Rheumatoid Arthritis
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
NCT00838565 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 41 participants.
The verdict
NCT00838565, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
This study will evaluate the safety and tolerability of PF-04236921 administered monthly as three intravenous infusions. Each group of patients will be assigned to a dose level; Safety and tolerability of a low dose level will be required before proceeding to successively higher dose levels. Blood tests will be performed to measure the amount of drug and changes in measures of inflammation.
Interventions
- DRUG Placebo
- DRUG dose level 1
- DRUG dose level 2
- DRUG dose level 3
- DRUG dose level 4
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2009-05-20 |
| Est. Completion | 2012-02-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00838565
The ClinicalTrials.gov registry entry for NCT00838565 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT00838565 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00838565 about?
NCT00838565 is a clinical study titled "Phase I Study Of The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Intravenously Administered Doses Of PF-04236921 In Patients With Rheumatoid Arthritis". This study will evaluate the safety and tolerability of PF-04236921 administered monthly as three intravenous infusions. Each group of patients will be assigned to a dose level; Safety and tolerability of a low dose level will be required before proceeding to successively higher dose levels. Blood t...
What is the current status of trial NCT00838565?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2009-05-20. Estimated completion is 2012-02-02.
What interventions are being tested in trial NCT00838565?
The interventions under investigation include: Placebo (DRUG), dose level 1 (DRUG), dose level 2 (DRUG), dose level 3 (DRUG), dose level 4 (DRUG).
Who is sponsoring clinical trial NCT00838565?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.